Home » Newsletters » BioWorld Science

BioWorld Science

April 11, 2011

View Archived Issues

Novel PLK4 inhibitors demonstrate antiproliferative activity in models of breast cancer

Arena Pharma describes new potent and selective lysophospholipid S1P1 receptor agonists

Frizzled SMO receptor inhibitor LY-2940680 exhibits antitumor effects in vivo

Nile Pax paclitaxel-eluting stent successfully treats coronary bifurcation lesions

Danoprevir/ritonavir shows anti-HCV efficacy in combination with P/R in P/R null reponders

Myrcludex B blocks spread of hepatitis B virus in infected humanized mice

Livatag improves survival of patients with advanced hepatocellular carcinoma

La Jolla Pharma focuses on regenerative medicine following acquisition of GliaMed's RILs

Bayer and Regeneron begin phase III VEGF Trap-Eye trial in diabetes-related macular edema

Acadia Pharma and Allergan extend eye care collaboration

New macrocyclic JAK3 inhibitors patented by Roche

Boehringer Ingelheim patents novel inhibitors of HCV NS5B

Merck & Co. prepares novel glucocorticoid receptor ligands

Sunovion reports new histamine H3 receptor antagonists/inverse agonists

U.S. researchers patent novel nucleoside phosphonates

Alnylam extends RNAi collaboration with AlCana and University of British Columbia

Novartis completes merger with Alcon, adding eye care as growth platform

Champions Oncology exercises option to license Irinophore C

Allergy Therapeutics submits MAA in Switzerland for Grass MATA MPL

FDA accepts Antares Pharma's Anturol NDA for filing

Nuron Biotech acquires Hibtiter conjugate vaccine assets from Wyeth

Sanofi-aventis completes acquisition of Genzyme

Novartis discontinues phase III Tasigna trial in gastrointestinal stromal tumors

Takeda and Heptares to research G protein-coupled receptor in CNS disorders

StemCells discontinues phase Ib HuCNS-SC trial in neuronal ceroid lipofuscinosis

FDA clears Cepheid Xpert C. difficile/Epi assay for CDI

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...